Monoallelic loss of tumor suppressor GRIM-19 promotes tumorigenesis in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 45, 2013, Pages

  Kalakonda, Sudhakar ^a,b   Nallar, Shreeram C ^a,b   Jaber, Sausan ^c,d   Keay, Susan K ^e,f   Rorke, Ellen ^a   Munivenkatappa, Raghava ^g,i   Lindner, Daniel J ^h   Fiskum, Gary M ^c   Kalvakolanu, Dhananjaya V ^a,b  

^a Departments of Microbiology and Immunology   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^c Departments of Anesthesiology   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e Departments of Medicine   (United States)

^f BALTIMORE VA MEDICAL CENTER   (United States)

^g Departments of Pathology   (United States)

^h TAUSSIG CANCER INSTITUTE   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Glucose metabolism; Immune response; Oxidative phosphorylation

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; ABC TRANSPORTER; ABC TRANSPORTER B5; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CARBONATE DEHYDRATASE XII; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYTOCHROME C OXIDASE; CYTOKERATIN 1; DIHYDROFOLATE REDUCTASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GENE ASSOCIATED WITH RETINOID INTERFERON INDUCED MORTALITY 19 PROTEIN; LACTIC ACID; OCTAMER TRANSCRIPTION FACTOR 2; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN BCL XL; PYRUVATE DEHYDROGENASE KINASE 2; PYRUVATE DEHYDROGENASE KINASE 4; PYRUVATE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); STAT3 PROTEIN; SUCCINATE DEHYDROGENASE (UBIQUINONE); TRANSCRIPTION FACTOR SOX2; TUMOR SUPPRESSOR PROTEIN; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; UVOMORULIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL SURVIVAL; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DNA MODIFICATION; ELECTRON TRANSPORT; EXON; FEMALE; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE ISOLATION; GENE SILENCING; GENETIC MANIPULATION; GENETIC SUSCEPTIBILITY; GENOTYPE; GLUCOSE INTAKE; GLYCOLYSIS; HETEROZYGOTE; IN VIVO STUDY; INTRON; LOXP SITE; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; WILD TYPE;

CYTOKINES; GLUCOSE METABOLISM; IMMUNE RESPONSE; OXIDATIVE PHOSPHORYLATION;

ANIMALS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; DNA PRIMERS; GENE COMPONENTS; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; NADH, NADPH OXIDOREDUCTASES; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, RNA; STAT3 TRANSCRIPTION FACTOR;

EID: 84887292325     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1303760110     Document Type: Article

References (93)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144 (5):646-674.
2. Kalvakolanu DV (2004) The GRIMs: A new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev 15(2-3):169-194.
3. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235-271.
4. Critchley-Thorne RJ, et al. (2009) Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA 106(22):9010-9015.
5. Burnette BC, et al. (2011) The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 71(7):2488-2496.
6. Weichselbaum RR, et al. (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 105(47):18490-18495.
7. Chan SR, et al. (2012) STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res 14(1):R16.
8. Taniguchi T, Lamphier MS, Tanaka N (1997) IRF-1: The transcription factor linking the interferon response and oncogenesis. Biochim Biophys Acta 1333(1):M9-M17.
9. Bidwell BN, et al. (2012) Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18(8):1224-1231.
10. Holtschke T, et al. (1996) Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87(2):307-317.
11. Willman CL, et al. (1993) Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 259(5097):968-971.
12. Schmidt M, et al. (1998) Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 91(1):22-29.
13. Angell JE, Lindner DJ, Shapiro PS, Hofmann ER, Kalvakolanu DV (2000) Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem 275(43): 33416-33426.
14. Zhang J, et al. (2003) The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci USA 100(16): 9342-9347.
15. Lufei C, et al. (2003) GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J 22(6):1325-1335.
16. Nallar SC, et al. (2013) Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis. J Biol Chem 288(11):7930-7941.
17. Lippman SM, et al. (1992) 13-cis-retinoic acid plus interferon alpha-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84(4): 241-245.
18. Lippman SM, et al. (1992) 13-cis-retinoic acid and interferon alpha-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84(4):235-241.
19. Zhou Y, et al. (2009) Down-regulation of GRIM-19 expression is associated with hyperactivation of STAT3-induced gene expression and tumor growth in human cervical cancers. J Interferon Cytokine Res 29(10):695-703.
20. Hecht SS (2002) Tobacco smoke carcinogens and breast cancer. Environ Mol Mutagen 39(2-3):119-126.
21. Iguchi T, Irisawa S, Uchima FD, Takasugi N (1988) Permanent chondrification in the pelvis and occurrence of hernias in mice treated neonatally with tamoxifen. Reprod Toxicol 2(2):127-134.
22. Suiqing C, Min Z, Lirong C (2005) Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol 32(5):354-360.
23. Chan KS, et al. (2004) Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res 64(7):2382-2389.
24. Pedranzini L, Leitch A, Bromberg J (2004) Stat3 is required for the development of skin cancer. J Clin Invest 114(5):619-622.
25. Jeanes A, Gottardi CJ, Yap AS (2008) Cadherins and cancer: How does cadherin dysfunction promote tumor progression? Oncogene 27(55):6920-6929.
26. Chan KS, et al. (2004) Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 114(5):720-728.
27. Takahashi K, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861-872.
28. Kalakonda S, et al. (2013) GRIM-19 mutations fail to inhibit v-Src-induced oncogenesis. Oncogene, 10.1038/onc.2013.271.
29. Fukunaga-Kalabis M, Herlyn M (2012) Beyond ABC: Another mechanism of drug resistance in melanoma side population. J Invest Dermatol 132(10):2317-2319.
30. Heckman CA, Duan H, Garcia PB, Boxer LM (2006) Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression. Oncogene 25(6):888-898.
31. Aguirre-Cruz L, et al. (2004) Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors. J Neurooncol 67(3):265-271.
32. Barnett DH, et al. (2008) Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res 68(9):3505-3515.
33. Yoo CW, et al. (2010) Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome. Radiat Oncol 5:101.
34. Dauer DJ, et al. (2005) Stat3 regulates genes common to both wound healing and cancer. Oncogene 24(21):3397-3408.
35. Croker BA, et al. (2003) SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4(6):540-545.
36. Lang R, et al. (2003) SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 4(6):546-550.
37. Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S (2002) Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100(8):2926-2931.
38. Chung CD, et al. (1997) Specific inhibition of Stat3 signal transduction by PIAS3. Science 278(5344):1803-1805.
39. Levy C, Nechushtan H, Razin E (2002) A new role for the STAT3 inhibitor, PIAS3: A repressor of microphthalmia transcription factor. J Biol Chem 277(3):1962-1966.
40. Sundvall M, et al. (2012) Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein. J Biol Chem 287(27):23216-23226.
41. Kalakonda S, et al. (2007) Tumor-suppressive activity of the cell death activator GRIM- 19 on a constitutively active signal transducer and activator of transcription 3. Cancer Res 67(13):6212-6220.
42. Seo T, et al. (2002) Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus interacts with a cell death regulator, GRIM19, and inhibits interferon/retinoic acid-induced cell death. J Virol 76(17):8797-8807.
43. Zhou Y, et al. (2011) GRIM-19 disrupts E6/E6AP complex to rescue p53 and induce apoptosis in cervical cancers. PLoS ONE 6(7):e22065.
44. Zhang L, et al. (2008) Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth. Clin Cancer Res 14(2):559-568.
45. Gong LB, et al. (2007) [Correlations of GRIM-19 and its target gene product STAT3 to malignancy of human colorectal carcinoma]. Ai Zheng 26(7):683-687.
46. Zhou AM, et al. (2009) [Expression and clinical significance of GRIM-19 in non-small cell lung cancer]. Ai Zheng 28(4):431-435.
47. Okamoto T, et al. (2010) Overexpression of GRIM-19 in cancer cells suppresses STAT3- mediated signal transduction and cancer growth. Mol Cancer Ther 9(8):2333-2343.
48. Hao H, et al. (2012) Depletion of GRIM-19 accelerates hepatocellular carcinoma invasion via inducing EMT and loss of contact inhibition. J Cell Physiol 227(3): 1212-1219.
49. Zhang Y, et al. (2011) Downregulation of GRIM-19 promotes growth and migration of human glioma cells. Cancer Sci 102(11):1991-1999.
50. Fan XY, Jiang ZF, Cai L, Liu RY (2012) Expression and clinical significance of GRIM-19 in lung cancer. Med Oncol 29(5):3183-3189.
51. Li F, et al. (2012) Downregulation of GRIM-19 is associated with hyperactivation of p-STAT3 in hepatocellular carcinoma. Med Oncol 29(5):3046-3054.
52. Máximo V, et al. (2005) Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion- rich (Hurthle cell) tumours of the thyroid. Br J Cancer 92(10):1892-1898.
53. Huang G, et al. (2004) GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I. Mol Cell Biol 24(19):8447-8456.
54. Akira S (2000) Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 19(21):2607-2611.
55. Chan KS, et al. (2008) Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by twostage carcinogenesis. Oncogene 27(8):1087-1094.
56. Leslie K, et al. (2006) Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 66(5):2544-2552.
57. Masuda M, et al. (2010) Stat3 orchestrates tumor development and progression: The Achilles' heel of head and neck cancers? Curr Cancer Drug Targets 10(1):117-126.
58. Jian Y, et al. (2005) Cyclin D3 interacts with vitamin D receptor and regulates its transcription activity. Biochem Biophys Res Commun 335(3):739-748.
59. Ratineau C, Petry MW, Mutoh H, Leiter AB (2002) Cyclin D1 represses the basic helixloop- helix transcription factor, BETA2/NeuroD. J Biol Chem 277(11):8847-8853.
60. Zwijsen RM, et al. (1997) CDK-independent activation of estrogen receptor by cyclin D1. Cell 88(3):405-415.
61. Loyer P, Trembley JH, Katona R, Kidd VJ, Lahti JM (2005) Role of CDK/cyclin complexes in transcription and RNA splicing. Cell Signal 17(9):1033-1051.
62. Kaplan DH, et al. (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95(13): 7556-7561.
63. Bachmann IM, et al. (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24(2):268-273.
64. Chen B, et al. (2013) JNK and STAT3 signaling pathways converge on Akt-mediated phosphorylation of EZH2 in bronchial epithelial cells induced by arsenic. Cell Cycle 12(1):112-121.
65. Tataroglu C, Karabacak T, Apa DD (2007) Beta-catenin and CD44 expression in keratoacanthoma and squamous cell carcinoma of the skin. Tumori 93(3):284-289.
66. Bhatia N, Spiegelman VS (2005) Activation of Wnt/beta-catenin/Tcf signaling in mouse skin carcinogenesis. Mol Carcinog 42(4):213-221.
67. Yue Z, Jin S, Yang C, Levine AJ, Heintz N (2003) Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 100(25):15077-15082.
68. Qu X, et al. (2003) Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 112(12):1809-1820.
69. Shao LJ, Shi HY, Ayala G, Rowley D, Zhang M (2008) Haploinsufficiency of the maspin tumor suppressor gene leads to hyperplastic lesions in prostate. Cancer Res 68(13): 5143-5151.
70. Kwabi-Addo B, et al. (2001) Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 98(20):11563-11568.
71. Fang Y, et al. (2004) ATR functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient background. EMBO J 23(15):3164-3174.
72. Srivastava M, et al. (2003) Haploinsufficiency of Anx7 tumor suppressor gene and consequent genomic instability promotes tumorigenesis in the Anx7(+/-) mouse. Proc Natl Acad Sci USA 100(24):14287-14292.
73. Goss KH, et al. (2002) Enhanced tumor formation in mice heterozygous for Blm mutation. Science 297(5589):2051-2053.
74. Schwarz M, Munzel PA, Braeuning A (2013) Non-melanoma skin cancer in mouse and man. Arch Toxicol 87(5):783-798.
75. Simonnet H, et al. (2002) Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 23(5):759-768.
76. Alchanati I, et al. (2006) A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 25(54): 7138-7147.
77. Pagniez-Mammeri H, et al. (2012) Mitochondrial complex I deficiency of nuclear origin I. Structural genes. Mol Genet Metab 105(2):163-172.
78. Lemarie A, Grimm S (2011) Mitochondrial respiratory chain complexes: Apoptosis sensors mutated in cancer? Oncogene 30(38):3985-4003.
79. Baysal BE, et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287(5454):848-851.
80. Ricketts C, et al. (2008) Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 100(17):1260-1262.
81. Gough DJ, et al. (2009) Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324(5935):1713-1716.
82. Ritterson Lew C, Tolan DR (2012) Targeting of several glycolytic enzymes using RNA interference reveals aldolase affects cancer cell proliferation through a non-glycolytic mechanism. J Biol Chem 287(51):42554-42563.
83. Mamczur P, Gamian A, Kolodziej J, Dziegiel P, Rakus D (2013) Nuclear localization of aldolase A correlates with cell proliferation. Biochim Biophys Acta 1833(12): 2812-2822.
84. Yang W, et al. (2012) PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150(4):685-696.
85. Yang W, et al. (2011) Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480(7375):118-122.
86. Gao X, Wang H, Yang JJ, Liu X, Liu ZR (2012) Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 45(5):598-609.
87. Zhang X, et al. (2013) Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol Res Pract 209(8):510-515.
88. Wigfield SM, et al. (2008) PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br J Cancer 98(12):1975-1984.
89. Sun W, Chang SS, Fu Y, Liu Y, Califano JA (2011) Chronic CSE treatment induces the growth of normal oral keratinocytes via PDK2 upregulation, increased glycolysis and HIF1α stabilization. PLoS ONE 6(1):e16207.
90. Contractor T, Harris CR (2012) p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res 72(2):560-567.
91. Prizment AE, Gross M, Rasmussen-Torvik L, Peacock JM, Anderson KE (2012) Genes related to diabetes may be associated with pancreatic cancer in a population-based case-control study in Minnesota. Pancreas 41(1):50-53.
92. Gottfried E, Kreutz M, Mackensen A (2012) Tumor metabolism as modulator of immune response and tumor progression. Semin Cancer Biol 22(4):335-341.
93. Fischer K, et al. (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109(9):3812-3819.